The impact of carvedilol coadministration on enantioselective lercanidipine pharmacokinetics in patients with chronic kidney disease

被引：0
|
作者：
Schaab, Estela H.
Lanchote, Vera L.
Paiva, Carlos E. [1 ]
Dantas, Marcio [1 ]
Coelho, Eduardo B. [1 ]
机构：
[1] Univ Sao Paulo, Med Clin, BR-14049 Ribeirao Preto, Brazil
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 51卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1358 / 1358
页数：1
相关论文
共 50 条
  • [31] A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease
    Malik, Paul R. V.
    Yeung, Cindy H. T.
    Ismaeil, Shams
    Advani, Urooj
    Djie, Sebastian
    Edginton, Andrea N.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 : S52 - S62
  • [32] EFFECTS OF ACE INHIBITOR PERINDOPRIL AND CALCIUM ANTAGONIST LERCANIDIPINE ON LIPIDS PROFILE IN HYPERTENSIVE PATIENTS WITH CHRONIC KIDNEY DISEASE
    Bezrodna, L.
    Svyshchenko, Y.
    Bezrodnyy, V.
    Mishchenko, L.
    JOURNAL OF HYPERTENSION, 2010, 28 : E380 - E380
  • [33] Pharmacokinetics of estroeen and progesterone in chronic kidney disease
    Anderson, GD
    Odegard, PS
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2004, 11 (04) : 357 - 360
  • [34] Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
    Navarro-Gonzales, Pamela
    Ganz, Tomas
    Pergola, Pablo E.
    Zuk, Anna
    Dykstra, Kevin
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (04) : 1052 - 1061
  • [35] Population pharmacokinetics and dose optimisation of colecalciferol in paediatric patients with chronic kidney disease
    Wan, Mandy
    Green, Bruce
    Iyengar, Arpana Aprameya
    Kamath, Nivedita
    Reddy, Hamsa V.
    Sharma, Jyoti
    Singhal, Jyoti
    Uthup, Susan
    Ekambaram, Sudha
    Selvam, Sumithra
    Rait, Greta
    Shroff, Rukshana
    Patel, Jignesh P.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (03) : 1223 - 1234
  • [36] Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease
    Wang, Evan B.
    Chaudhary, Archana
    Waterhouse, Timothy H.
    Dickinson, Gemma L.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (06): : 739 - 746
  • [37] Pharmacokinetics (PK) of Aranesp® (darbepoetin alfa) in patients with chronic kidney disease (CKD)
    Padhi, D
    Jang, G
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V255 - V255
  • [38] Diabetes mellitus has the prognostic impact in chronic heart failure patients with chronic kidney disease but not without chronic kidney disease
    Fukunami, MMasatake
    Yamada, T.
    Morita, T.
    Furukawa, Y.
    Tamaki, S.
    Iwasaki, Y.
    Kawasaki, M.
    Kikuchi, A.
    Kondoh, T.
    EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 322 - 322
  • [39] Impact of obesity on vascular calcification in patients with chronic kidney disease
    Uhlinova, Jana
    Kuudeberg, Anne
    Denissova, Alina
    Ilves, Pilvi
    Lember, Margus
    Ots-Rosenberg, Mai
    CLINICAL NEPHROLOGY, 2022, 97 (01) : 10 - 17
  • [40] IMPACT OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH AS USING BIOLOGIC AGENTS
    Uzun, G. Sandal
    Cakir, I. Y.
    Bilgin, E.
    Farisogullari, B.
    Ayan, G.
    Ozsoy, Z.
    Ekici, M.
    Unaldi, E.
    Germe, S. A.
    Firlatan, B.
    Bayram, G. S. Kart
    Kilic, L.
    Karadag, O.
    Akdogan, A.
    Bilgen, S. A.
    Kiraz, S.
    Ertenli, A. I.
    Kalyoncu, U.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1695 - 1695
12345